Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:9053 |
| Name | bladder carcinoma in situ |
| Definition | An in situ carcinoma that is located_in the bladder. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation pre-malignant neoplasm in situ carcinoma bladder carcinoma in situ |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03091660 | Phase III | BCG Tokyo-172 Strain Solution BCG solution | Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
| NCT06390111 | Expanded access | Nadofaragene firadenovec | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. (ABLE-42) | Withdrawn | USA | 0 |
| NCT07206225 | Phase I | PF-08052667 BCG solution + PF-06801591 + PF-08052667 PF-06801591 + PF-08052667 | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Recruiting | USA | ISR | GBR | FRA | ESP | 1 |